These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36831034)

  • 1. Does the SARS-CoV-2 Spike Receptor-Binding Domain Hamper the Amyloid Transformation of Alpha-Synuclein after All?
    Stroylova Y; Konstantinova A; Stroylov V; Katrukha I; Rozov F; Muronetz V
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between SARS-CoV-2 N-Protein and α-Synuclein Accelerate Amyloid Formation.
    Semerdzhiev SA; Fakhree MAA; Segers-Nolten I; Blum C; Claessens MMAE
    ACS Chem Neurosci; 2022 Jan; 13(1):143-150. PubMed ID: 34860005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration.
    Idrees D; Kumar V
    Biochem Biophys Res Commun; 2021 May; 554():94-98. PubMed ID: 33789211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.
    Kalathiya U; Padariya M; Fahraeus R; Chakraborti S; Hupp TR
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation.
    Jawad B; Adhikari P; Podgornik R; Ching WY
    J Chem Inf Model; 2021 Sep; 61(9):4425-4441. PubMed ID: 34428371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.
    Othman H; Bouslama Z; Brandenburg JT; da Rocha J; Hamdi Y; Ghedira K; Srairi-Abid N; Hazelhurst S
    Biochem Biophys Res Commun; 2020 Jun; 527(3):702-708. PubMed ID: 32410735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an Amyloidogenic SARS-COV-2 Protein Fragment on α-Synuclein Monomers and Fibrils.
    Jana AK; Lander CW; Chesney AD; Hansmann UHE
    J Phys Chem B; 2022 May; 126(20):3648-3658. PubMed ID: 35580331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2.
    Nguyen K; Chakraborty S; Mansbach RA; Korber B; Gnanakaran S
    Viruses; 2021 May; 13(5):. PubMed ID: 34067878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis.
    Khater I; Nassar A
    Inform Med Unlocked; 2022; 29():100873. PubMed ID: 35136832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
    Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
    BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction.
    Eka Saputri M; Aisyah Rahmalia Effendi S; Nadila R; Azzam Fajar S; Damajanti Soejoedono R; Handharyani E; Nadia Poetri O
    Int Immunopharmacol; 2022 Nov; 112():109280. PubMed ID: 36183680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
    Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
    Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.